PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
Citations Over TimeTop 1% of 2015 papers
Abstract
Prostate cancer (PCa) is the most common malignancy in men worldwide, leading to substantial morbidity and mortality. At present, imaging of PCa has become increasingly important for staging, restaging, and treatment selection. Until recently, choline-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging technique for these purposes. However, its application is limited to patients with high PSA levels and Gleason scores. Prostate-specific membrane antigen (PSMA) is a promising new target for specific imaging of PCa, because it is upregulated in the majority of PCa. Moreover, PSMA can serve as a target for therapeutic applications. Currently, several small-molecule PSMA ligands with excellent in vivo tumor targeting characteristics are being investigated for their potential in theranostic applications in PCa. Here, a review of the recent developments in PSMA-based diagnostic imaging and therapy in patients with PCa with radiolabeled PSMA ligands is provided.
Related Papers
- → Molecular probes for the in vivo imaging of cancer(2009)73 cited
- → Synthesis and Evaluation of GdIII‐Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate‐Specific Membrane Antigen(2015)66 cited
- → In Vivo Molecular Imaging for Biomedical Analysis and Therapies(2018)16 cited
- → In vivo molecular and single cell imaging(2022)9 cited
- → Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer(2019)